Argenx, a global immunology company dedicated to improving the lives of individuals with severe autoimmune diseases, announced today that members of their management team will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 10:00 AM PT in Las Vegas, NV. The chat will be accessible via a live webcast on the Investors section of the argenx website, with a replay available for approximately 90 days after the event.
Argenx’s mission is to partner with leading academic researchers through its Immunology Innovation Program (IIP) to develop novel antibody-based medicines that stem from immunology breakthroughs. The company is currently commercializing the first approved neonatal Fc receptor (FcRn) blocker in various countries, including the U.S., Japan, and the EU. Additionally, they are evaluating efgartigimod in multiple serious autoimmune diseases and advancing other experimental medicines within their therapeutic franchises.
For more information about argenx and their mission, you can visit their website at www.argenx.com and follow them on social media platforms such as LinkedIn, Twitter, Instagram, Facebook, and YouTube. For media or investor inquiries, you can contact Ben Petok for media relations and Alexandra Roy or Lynn Elton for investor relations.
